Isabel Oliveira

Mr. Isabel Oliveira

3 B`s Research Group
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2018 in Nano Research
Verified
Journal Article
Closed access
PDF file
IOIsabel Oliveira
Isabel Oliveira
Cristiana GonçalvesCristiana Gonçalves
Cristiana Gonçalves
RRRui Luís Reis
Rui Luís Reis
Joaquim OliveiraJoaquim Oliveira
Joaquim Oliveira
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by synovial joint inflammation and cartilage and bone tissue destruction. Although there exist some treatment strategies for RA, they are not completely safe and effective. Therefore, it is important to develop and test new drugs for RA that specifically target inflamed/swollen joints and simultaneously attenuate other possible damages to healthy tissues. Nanotechnology can be a good alternative to consider when envisioning precise medication for treating RA. Through the use of nanoparticles, it is possible to increase bioavailability and bioactivity of therapeutics and enable selective targeting to damaged joints. Herein, recent studies using nanoparticles for the treatment of RA, namely with liposomes, polymeric nanoparticles, dendrimers, and metallic nanoparticles, have been reviewed. These therapeutic strategies have shown great promise in improving the treatment over that by traditional drugs. The results of these studies confirm that feasibility of the use of nanoparticles is mainly due to their biocompatibility, low toxicity, controlled release, and selective drug delivery to inflamed tissues in animal RA models. Therefore, it is possible to claim that nanotechnology will, in the near future, play a crucial role in advanced treatments and patient-specific therapies for human diseases such as RA.

1 February 2021 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
IOIsabel Oliveira
Isabel Oliveira
Cristiana GonçalvesCristiana Gonçalves
Cristiana Gonçalves
EOEduarda Pinheiro Oliveira
Eduarda Pinheiro Oliveira
RSRosana Simón-Vázquez
Rosana Simón-Vázquez
AMAlain da Silva Morais
Alain da Silva Morais
Joaquim OliveiraJoaquim Oliveira
Joaquim Oliveira

17 October 2020 in Biomolecules
Verified
Journal Article
Open access
PDF file
IOIsabel Oliveira
Isabel Oliveira
Cristiana GonçalvesCristiana Gonçalves
Cristiana Gonçalves
MSMyeong Eun Shin
Myeong Eun Shin
SLSumi Lee
Sumi Lee
RRRui M. Reis
Rui M. Reis
Joaquim OliveiraJoaquim Oliveira
Joaquim Oliveira
Rheumatoid arthritis is a rheumatic disease for which a healing treatment does not presently exist. Silk fibroin has been extensively studied for use in drug delivery systems due to its uniqueness, versatility and strong clinical track record in medicine. However, in general, natural polymeric materials are not mechanically stable enough, and have high rates of biodegradation. Thus, synthetic materials such as gellan gum can be used to produce composite structures with biological signals to promote tissue-specific interactions while providing the desired mechanical properties. In this work, we aimed to produce hydrogels of tyramine-modified gellan gum with silk fibroin (Ty–GG/SF) via horseradish peroxidase (HRP), with encapsulated betamethasone, to improve the biocompatibility and mechanical properties, and further increase therapeutic efficacy to treat rheumatoid arthritis (RA). The Ty–GG/SF hydrogels presented a β-sheet secondary structure, with gelation time around 2–5 min, good resistance to enzymatic degradation, a suitable injectability profile, viscoelastic capacity with a significant solid component and a betamethasone-controlled release profile over time. In vitro studies showed that Ty–GG/SF hydrogels did not produce a deleterious effect on cellular metabolic activity, morphology or proliferation. Furthermore, Ty–GG/SF hydrogels with encapsulated betamethasone revealed greater therapeutic efficacy than the drug applied alone. Therefore, this strategy can provide an improvement in therapeutic efficacy when compared to the traditional use of drugs for the treatment of rheumatoid arthritis.

21 July 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
IOIsabel Oliveira
Isabel Oliveira
DFDiogo Castro Fernandes
Diogo Castro Fernandes
F.Raquel MaiaF.Raquel Maia
F.Raquel Maia
RCRaphael F. Canadas
Raphael F. Canadas
RRRui M. Reis
Rui M. Reis
Joaquim OliveiraJoaquim Oliveira
Joaquim Oliveira
Rheumatoid Arthritis (RA) is an incurable autoimmune disease that promotes the chronic impairment of patients’ mobility. For this reason, it is vital to develop therapies that target early inflammatory symptoms and act before permanent articular damage. The present study offers two novel therapies based in advanced drug delivery systems for RA treatment: encapsulated chondroitin sulfate modified poly(amidoamine) dendrimer nanoparticles (NPs) covalently bonded to monoclonal anti-TNF α antibody in both Tyramine-Gellan Gum and Tyramine-Gellan Gum/Silk Fibroin hydrogels. Using pro-inflammatory THP-1 (i.e., human monocytic cell line), the therapy was tested in an inflammation in vitro model under both static and dynamic conditions. Firstly, we demonstrated effective NP-antibody functionalization and TNF-α capture. Upon encapsulation, the NPs were released steadily over 21 days. Moreover, in static conditions, the approaches presented good anti-inflammatory activity over time, enabling the retainment of a high percentage of TNF α. To mimic the physiological conditions of the human body, the hydrogels were evaluated in a dual-chamber bioreactor. Dynamic in vitro studies showed absent cytotoxicity in THP-1 cells and a significant reduction of TNF-α in suspension over 14 days for both hydrogels. Thus, the developed approach showed potential for use as personalized medicine to obtain better therapeutic outcomes and decreased adverse effects.

8 May 2018
Verified
Book Chapter
Closed access
PDF file
IOIsabel Oliveira
Isabel Oliveira
ACAna L. Carvalho
Ana L. Carvalho
Hajer RadhouaniHajer Radhouani
Hajer Radhouani
Cristiana GonçalvesCristiana Gonçalves
Cristiana Gonçalves
Joaquim OliveiraJoaquim Oliveira
Joaquim Oliveira
RRRui L. Reis
Rui L. Reis

1 January 2021
Verified
Book Chapter
Closed access
IOIsabel Oliveira
Isabel Oliveira
MCMariana R. Carvalho
Mariana R. Carvalho
RRRui L. Reis
Rui L. Reis
JOJoaquim M. Oliveira
Joaquim M. Oliveira